Press Releases

Pfizer Inc announced results of two Phase 3 studies demonstrating the immunogenicity of TRUMENBA® (Meningococcal Group B Vaccine) against invasive meningococcal B (MnB) strains representative of prevalent strains in the U.S. and Europe. The two studies,...

Pfizer Inc announced results of two Phase 3 studies demonstrating the immunogenicity of TRUMENBA® (Meningococcal Group B Vaccine) against invasive meningococcal B (MnB) strains representative of prevalent strains in the U.S. and Europe.   ]The two...

First Fc Fusion Therapy Approved for haemophilia B in the EU to Provide Extended Protection Against Bleeds Swedish Orphan Biovitrum AB and Biogen announced that the European Commission (EC) has approved Alprolix® (rFIXFc), their extended half-life...

Mylan N.V. announced the U.S. launch of Frovatriptan Succinate Tablets 2.5 mg, a generic version of Endo's Frova® Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for...

AbbVie will participate in the UBS Global Healthcare Conference on Monday, May 23, 2016. Bill Chase, executive vice president and chief financial officer, will participate in a question and answer session at 1:00 p.m. Central time. ...

First and only immunostimulatory antibody approved in the European Union for multiple myeloma Accelerated assessment and approval based on long-term data from ELOQUENT-2, which evaluated Empliciti in combination with Revlimid®(lenalidomide) and dexamethasone (Rd). ELOQUENT-2 demonstrated...

Opdivo + Yervoy Regimen now approved for unresectable or metastatic melanoma patients, regardless of BRAF mutational status Approval of the Regimen marks a novel combination treatment for advanced melanoma patients, demonstrating the potential of targeting distinct and...